ADC Therapeutics SA, based in Lausanne, Switzerland, has announced the issuance of stock options to two new employees as part of its Inducement Plan. On June 2, 2025, the company granted options to purchase a total of 107,550 common shares. These grants were approved by the Compensation Committee and are structured to vest over a four-year period. Initially, 25% of the options will become exercisable on the first anniversary of the grant date, with an additional 1/48th of the shares vesting monthly thereafter, contingent upon continued employment with the company.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。